🚀 Medial Secures Investment on Shark Tank India - Fueling the Future of Professional Social Networking. 🔥
✕
Login
Home
News
Messages
Startup Showcase
Trackers
Premium
Premium Content
Jobs
Notifications
Settings
Try our Valuation Calculator →
Log In
News on Medial
Zydus Lifesciences shares - Zydus Lifesciences gets final nod from USFDA for 'Dasatinib' tablets. Details here - Zydus Lifesciences gets final nod from USFDA for 'Dasatinib' tablets
Business Today
·
5m ago
Medial
Zydus Lifesciences Ltd received final USFDA approval for Dasatinib tablets in various strengths. Dasatinib treats newly diagnosed adults with Philadelphia chromosome-positive chronic myeloid leukaemia (CML) in chronic phase, as well as adults with chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML resistant or intolerant to prior therapy, including imatinib. It also addresses adult patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia (Ph+ ALL) showing resistance or intolerance to previous treatments.
View Source
1
Related News
Zydus Life gets USFDA approval for Fludrocortisone Acetate tablets; shares trade flat
Money Control
·
9m ago
Medial
Zydus Lifesciences has received final approval from the US Food and Drug Administration (FDA) to produce Fludrocortisone Acetate Tablets USP, 0.1 mg. The tablets are used for partial replacement therapy in certain adrenal gland disorders. This latest approval brings Zydus Lifesciences' total number of approved products to 400, with over 465 ANDA filings since 2003. The tablets will be manufactured at their facility in Moraiya, Ahmedabad. Earlier this month, the company also entered into an agreement with the Indian Council of Medical Research for clinical trials of Desidustat in Sickle Cell Disease patients.
View Source
Stock Radar: Eicher Motors, Hero MotoCorp, Mankind Pharma, Ashoka Buildcon, KRN Heat, ITC in focus on Thursday
Money Control
·
10m ago
Medial
- Mankind Pharma receives regulatory approvals for the acquisition of Bharat Serums and Vaccines. - Zydus Lifesciences gets tentative approval from the USFDA for manufacturing Enzalutamide tablets. - Ashoka Buildcon receives the letter of award for multiple infrastructure projects worth crores. - Royal Enfield sales increase by 11% YoY, surpassing analysts' estimates. - Hero MotoCorp reports sales of 6.37 lakh units, beating analysts' expectations. - Maruti Suzuki India records a 1.9% increase in total sales, driven by higher exports.
View Source
Temasek-backed firm, Zydus may recast API, gelatine business of Sterling Biotech
VCCircle
·
11m ago
Medial
Zydus Lifesciences Ltd and Perfect Day Inc, the owners of Sterling Biotech, intend to restructure certain aspects of their joint venture. This includes plans to revamp the active pharmaceutical ingredient (API) and gelatine businesses. Zydus Lifesciences previously entered into a partnership agreement with Temasek-backed food technology company. No further details were provided.
View Source
Glenmark gets USFDA nod for bioequivalent of drug with market size of $21.9 million
Money Control
·
1y ago
Medial
Glenmark Pharmaceuticals has received final approval from the FDA for its Topiramate Capsules USP, used to treat epilepsy and seizures. The FDA has determined these capsules to be bioequivalent and therapeutic equivalent to a drug by Janssen Pharmaceuticals. The market for Topamax capsules has shown annual sales of around $21.9 million. Glenmark Pharma's US portfolio currently has 198 products authorized for distribution, with 50 ANDAs pending USFDA approval. The company's shares have seen a 65% increase this year and have doubled over the past year, but its consolidated net loss for the March quarter has widened.
View Source
Zydus Lifesciences ventures into medtech with acquisition of French firm
VCCircle
·
5m ago
Medial
Zydus Lifesciences Ltd has entered the medical technology sector by acquiring an 85.6% stake in the French orthopaedics firm Amplitude Surgical SA for €256.8 million. This acquisition, from PAI Partners and other shareholders, marks Zydus’ first outbound investment of 2025 and aligns with its strategy to diversify beyond its core business. The acquisition will help Zydus leverage Amplitude’s market presence and capabilities and may lead to a full acquisition valued at €300 million.
View Source
Zydus Healthcare appoints Swati Dalal MD
Economic Times
·
1m ago
Medial
Zydus Lifesciences Ltd has appointed Swati Dalal as the Managing Director of Zydus Healthcare Ltd, effective June 16, 2025, for a five-year term. Previously the Managing Director of Abbott India Ltd, Dalal brings over three decades of experience in the healthcare industry. Her career includes leadership roles at Abbott and a strong educational background, with a pharmacy degree from PKM Kundnani College and a postgraduate degree in Management Studies from Jamnalal Bajaj Institute, Mumbai.
View Source
Stripe gets final RBI nod for payment aggregator business
Inc42
·
1y ago
Medial
Global fintech startup Stripe has received final approval from the Reserve Bank of India (RBI) to operate as an online payment aggregator in India. Founded in 2010, Stripe offers a suite of fintech tools including billing and tax services. Zomato, a major foodtech company, also received approval from the RBI to operate as a payment aggregator. A total of 11 companies have received final approval from the RBI for online payment aggregator businesses. The regulatory framework for payment aggregators was introduced by the RBI in March 2020.
View Source
Paysharp Gets Payment Aggregator Nod From RBI
Inc42
·
11m ago
Medial
Paysharp, a Chennai-based fintech startup, has received final authorization from the Reserve Bank of India (RBI) to operate as a payment aggregator. Founded in 2019, the company has raised INR 23 Cr in funding and is currently valued at INR 200 Cr. Paysharp's business model revolves around providing flat pricing for merchants, with a specific focus on non-card-based payment solutions such as UPI and virtual accounts.
View Source
Revolut gets RBI nod for PPIs, wallets
Economic Times
·
4m ago
Medial
Revolut, a British fintech company, has obtained final approval from the Reserve Bank of India to issue Prepaid Payment Instruments (PPIs) in India, enabling services like prepaid cards and digital wallets with UPI integration. This authorization allows Revolut to offer both international and domestic payment solutions in India, entering the competitive digital payments market dominated by players like PhonePe and Google Pay. The move is part of Revolut's strategy to expand its global customer base.
View Source
Zerodha gets final nod for AMC licence from Sebi
Economic Times
·
1y ago
Medial
Zerodha, a leading Indian stock brokerage, receives final approval from SEBI for an Asset Management Company (AMC) license. This endorsement allows Zerodha to enter the asset management space, further expanding its financial services offerings. The approval underscores Zerodha's growth and diversification strategy, enabling it to cater to a wider range of investment and financial needs for its customers.
View Source
Trackers
Active Indian VC’s
OG Capital
Email
With a hands-on approach, OG Capital aims to invest in over 20 promising...
Accel Partners
Email
Early and growth-stage investments in disruptive technology companies with...
Blume
Email
Early-stage venture capital firm investing in technology startups in India. Focus on...
Access All Trackers
Startup Showcase Winners
June 2025
Buddy
Helping your parents when you are miles away
BiteStop
The Pit Stop Your Cravings Deserve
Bloomer
The next generation E-commerce platform
Enter Ongoing Startup Showcase
Top Users
Trending News on Medial
Download the medial app to read full posts, comements and news.
Go to Medial App
Not Now
Know everything that’s happening in the startup ecosystem, first.
Enable Notifications?
No, thanks
Count me in
